secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2024-12-09T23:59:59+00:00
Accession:  0001193125-24-272891
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vor Bio announces positive clinical data for trem-cel + Mylotarg in AML; FDA agrees on registrational trial design
--------------------------------------------------------------------------------

- Preliminary data shows median RFS not reached after 7.4 months follow-up in 15 AML patients treated with trem-cel + Mylotarg.
- Engraftment achieved in 100% of patients: neutrophil engraftment median 9.5 days, platelet recovery median 16 days.
- CD33 editing efficiency median 90% (range 71-94%); doses up to 2 mg/m2 without significant toxicity.
- FDA agreed on registrational trial design for trem-cel + Mylotarg, including study population, control arm, primary endpoint.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000119312524272891/0001193125-24-272891-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000119312524272891/d818014d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-272891

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer